<DOC>
	<DOCNO>NCT01631864</DOCNO>
	<brief_summary>This study investigate effect LCZ696 insulin sensitivity , lipolysis , oxidative metabolism obese hypertensive subject .</brief_summary>
	<brief_title>Evaluation Metabolic Effects LCZ696 Amlodipine Obese Hypertensive Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Written informed consent must obtain study assessment perform . Males females nonchildbearing potential ≥ 18 year age . Subjects mild moderate essential hypertension , Untreated subject must mean seat SBP ( msSBP ) ≥ 130 mmHg &lt; 180 mmHg screening . Pretreated subject must msSBP ≤ 160 mmHg screen &lt; 180 mmHg end washout period . Waist circumference ≥ 102 cm ( men ) ≥ 88 cm ( woman ) ; Exclusion criterion : Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer ; longer require local regulation . History angioedema , drugrelated otherwise History hypersensitivity LCZ696 , amlodipine , drug similar chemical class . Severe hypertension ( grade 3 WHO classification ; msDBP ≥100 mmHg and/or msSBP ≥ 180 mmHg ) screen end washout period . Type 1 Type 2 diabetes mellitus . Dyslipidemia require pharmacological therapy fibrate nicotinic acid . Concomitant use antihypertensive , antidiabetic , drug effect glucose lipid metabolism duration study . Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Hypertension , obesity , insulin sensitivity , lipolysis , LCZ696</keyword>
</DOC>